Vancouver, British Columbia — December 17, 2025 — Leads & Copy —
TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) has opened a new U.S. manufacturing facility in Florida to expand its production and meet rising demand for temperature-stable medication-storage devices. The additional site will increase capacity for healthcare organizations, pharmacies, payors, and device manufacturers, while also shortening delivery timelines and improving service for U.S. customers, where the majority of devices have been sold to date.
The new facility will support high-volume production of TempraMed’s core product line, including VIVI Cap™, VIVI Epi™, and the upcoming VIVI Box™ smart-storage platform. This expansion aims to improve delivery times, quality control, and supply-chain flexibility. Localized production within the U.S. is expected to reduce the cost of goods sold (COGS) through streamlined logistics, reduced import dependencies, and optimized manufacturing workflows.
According to Ron Nagar, CEO of TempraMed, the new manufacturing site marks a major step in strengthening the company’s U.S. presence and ensuring it can meet the accelerating needs of healthcare providers, pharmacies, payors, and strategic partners. Nagar said that domestic manufacturing provides the scale, speed, and reliability required to support the fastest-growing segments in temperature-sensitive medicine, including GLP-1 therapies, biologics, and self-injectables. He added that it directly supports the company’s commitment to delivering high-quality, cost-effective solutions that protect patients, reduce waste, and ease the operational burden on health systems.
The new site will operate alongside TempraMed’s existing global manufacturing network, providing redundancy, efficiency, and a scalable platform for future product introductions. The company anticipates continued growth in B2B demand as medication manufacturers, distributors, and healthcare systems adopt new standards for in-home and point-of-care temperature management.
Nagar added that expanding the U.S. manufacturing footprint strengthens every part of the business, including commercialization, cost structure, and customer satisfaction. He stated that it positions TempraMed to become the preferred partner for organizations seeking robust, compliant, and sustainable solutions for protecting high-value medications.
TempraMed Technologies Ltd. is headquartered in Israel with operations in North America, Europe, and Asia.
Julia Becker
Vice President, Capital Markets
T: +1 (604) 785-0850
E: julia@tempramed.com
Brenda Zeitlin
Vice President, Marketing
E: brenda@tempramed.com
Source: TempraMed Technologies Ltd.
